-
1 Comment
CSL Limited is currently in a long term downtrend where the price is trading 1.1% below its 200 day moving average.
From a valuation standpoint, the stock is 96.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.7.
CSL Limited's total revenue rose by 16.9% to $6B since the same quarter in the previous year.
Its net income has increased by 45.0% to $2B since the same quarter in the previous year.
Finally, its free cash flow grew by 1176.5% to $878M since the same quarter in the previous year.
Based on the above factors, CSL Limited gets an overall score of 4/5.
Sector | Healthcare |
---|---|
Exchange | AU |
CurrencyCode | AUD |
Industry | Biotechnology |
ISIN | AU000000CSL8 |
Target Price | 284.3648 |
---|---|
Dividend Yield | 1.4% |
Beta | 0.33 |
Market Cap | 103B |
PE Ratio | 22.33 |
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CSL.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025